Sustained-release verapamil and trandolapril, alone and in combination, in the treatment of obese hypertensive patients: A double-blind pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 12, 1996, Pages 990-997

  Nalbantgil, Istemi ^a,b   Önder, Remzi ^a   Nalbantgil, Sanem ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TRANDOLAPRIL; VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; MALE; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC);

EID: 0030483511     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80117-2     Document Type: Article

References (21)

1. Johnson AL, Cornoni JC, Cassel JC, et al. Influence of race, sex and weight on blood pressure behavior in young adults. Am J Cardiol. 1975;35:523-528.
2. Chiang BN, Perlman LV, Elpstein FH. Overweight and hypertension: A review. Circulation. 1969;39:403-421.
3. Stamler R, Stamler J, Riedlinger WF, et al. Weight and blood pressure: Findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607-1612.
4. Modan M, Halkin H, Almog S, et al. Hyperinsulinaemia: A link between hypertension, obesity and glucose intolerance. J Clin Invest. 1995;75:809-817.
5. Landsberg L. Pathophysiology of obesity-related hypertension: Role of insulin and the sympathetic nervous system. J Cardiovasc Pharmacol. 1994;23(Suppl 1):S1-S8.
6. James IM. Which antihypertensives? Br J Clin Pract. 1990;44:102-105.
7. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. NEJM. 1992;327:685-691.
8. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. NEJM. 1992;327:669-677.
9. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991;67:1295-1297.
10. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992;41:912-919.
11. Aursnes I, Litleskare I, Frøland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press. 1995;4:157-163.
12. Guidelines Subcommittee. 1993 Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens. 1993;11:905-918.
13. Wiseman LR, McTavish D. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994;48:71-90.
14. Snedecor GW, Cochran WG, eds. Statistical Method. 7th ed. Ames, Iowa: Iowa State University Press; 1980:91-116, 135-170.
15. Nalbantgil Í, Önder R, Kiliccioglu B, Türkoglu C. Combination therapy with verapamil and nitrendipine in patients with hypertension. J Hum Hypertens. 1993;7:305-308.
16. Zanchetti A. A re-examination of stepped-care. A retrospective and prospective study. J Cardiovasc Pharmacol. 1985;7(Suppl 1):S127-S131.
17. Gaillard CA, de Leeuw PW. Clinical experiences with trandolapril. Am Heart J. 1993; 125:1542-1546.
18. Weichenhain B, van Kooten HJ, Standl E. Hypertension and insulin resistance. Drugs. 1993;46(Suppl 2):183-188.
19. Zannad F. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs. 1993;46(Suppl 2):172-182.
20. Pledger G. The role of a placebo-treated control group in combination drug trials. Control Clin Trials. 1989;10:97-107.
21. Weidmann P, de Courten M, Boehlen L, Shaw S. The pathogenesis of hypertension in obese subjects. Drugs. 1993;46(Suppl 2):197-209.